Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1B | Q16820 | 12/20 | 0.65 |
| ▸ | MEP1A | Q16819 | 3/20 | 0.65 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.58 |
| ▸ | BCHE | P06276 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1456846 | 0.88 | MEP1B (0.60) | MEP1BMEP1AFOLH1BCHEMRGPRX4 | |
| Benzoic Acid SCHEMBL4162737 | 0.87 | MEP1B (0.55) | MEP1BMEP1ABCHELTA4H | |
| SCHEMBL11811255 | 0.87 | MEP1B (0.72) | MEP1BMEP1AFOLH1PTPN1 | |
| SCHEMBL8965622 | 0.87 | MEP1B (0.56) | MEP1BMEP1AFOLH1BCHELTA4H | |
| SCHEMBL15142867 | 0.86 | FOLH1 (0.54) | MEP1BMEP1AFOLH1MRGPRX4TP53 | |
| SCHEMBL40108 | 0.86 | MEP1B (0.51) | MEP1BMEP1AFOLH1BCHELTA4H | |
| SCHEMBL5915679 | 0.86 | POLB (0.57) | MEP1BMEP1ABCHETP53PKM | |
| SCHEMBL8173564 | 0.84 | MEP1B (0.66) | MEP1BMEP1ABCHEPTPN1 | |
| SCHEMBL4405810 | 0.84 | MEP1B (0.72) | MEP1BMEP1AFOLH1PTPN1 | |
| SCHEMBL29630981 | 0.84 | FOLH1 (0.59) | MEP1BMEP1AFOLH1MRGPRX4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1242408-B1 | SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION | HOFFMANN LA ROCHE (CH) | 2005-10-12 | — | — | EP | claimed |
| US-4305940-A | Benzamides with local anaesthetic and antiarrhythmic activity, salts, and method of preparation thereof and pharmaceutical compositions therefrom | B.B.R. BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) | 1981-12-15 | — | — | US | claimed |
| US-20090318396-A1 | CORTICOSTEROID LINKED BETA-AGONIST COMPOUNDS FOR USE IN THERAPY | GILEAD SCIENCES, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009152171-A1 | CORTICOSTEROID LINKED BETA-AGONIST COMPOUNDS FOR USE IN THERAPY | GILEAD SCIENCES, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| EP-1242408-B1 | SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION | HOFFMANN LA ROCHE (CH) | 2005-10-12 | — | — | EP | disclosed |
| EP-1242408-A1 | SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-25 | — | — | EP | disclosed |
| US-6313143-B1 | USEFUL IN THERAPY OF CELL PROLIFERATIVE DISORDERS SUCH AS CANCER | HOFFMANN-LA ROCHE INC. | 2001-11-06 | — | — | US | disclosed |
| WO-2001044234-A1 | SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318396-A1 | CORTICOSTEROID LINKED BETA-AGONIST COMPOUNDS FOR USE IN THERAPY | ADRB1, ADRB2, ADRB3 | MEP1B 1278/4885MEP1A 2716/4885FOLH1 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.